North America Cancer Therapy Market
The North American cancer therapy market is expected to grow at a CAGR of XX% and reach USD XXmillion by 2022.Cancer is a malignant growth caused by uncontrolled division ofcells in a part of body. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, demand for quality cancer treatments also has risen dramatically which is contributing to the growth of the market.
The end-users of this market are clinics, hospitals and research centers. Lung cancer, breast cancer, colorectal cancers, ovarian cancer, head and neck cancer, stomach cancer and liver cancer are some of the common cancers with increased treatment options in North America.
Rise in cancer incidence
Increasing access to modern therapeutics
Increasing geriatric population
Increase in innovations, improvements and approvals
The major restraints to the growth of the market are the high prices of therapy, change in reimbursement policies, and challenges faced in clinical trials.
The cancer therapy market is segmented based on therapy into targeted cancer therapy (hormone therapy, signal transduction inhibitors, gene expression modulators, apoptosis inducers, etc.), immunotherapy (monoclonal antibodies, cancer vaccines, non-specific immunotherapy), and chemotherapy. Based on geography, North America market is segmented into USA, Mexico and Canada.
Some of the key players in this market include –
Chugai Pharmaceutical Co., Ltd.
GPC Biotech AG
OSI Pharmaceuticals, Inc.
Market analysis for the North American cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market.
Identification and analysis of the macro and micro factors that affect the North American cancer therapy market.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Market Drivers, Restraints, Opportunities and Challenges (DROC) Analysis
6.1 Market Drivers
6.1.1 Rise in Cancer Incidence and Access to Modern Therapeutics
6.1.2 Increasing Aging Population
6.1.3 Innovations, Improvements and Approvals
6.2 Market Restraints
6.2.1 High Price of Therapy
6.2.2 Change in Reimbursement Policies
6.2.3 Challenges Encountered in Clinical Trials
6.3 Market Challenges
6.4 Market Opportunities
7. Market Segmentation
7.1 Market Segmentation by Types of Cancer
7.1.1 Blood Cancer
7.1.2 Bone Cancer
7.1.3 Brain Cancer
7.1.4 Breast Cancer
7.1.5 Digestive/ Gastrointestinal Cancer
7.1.6 Endocrine Cancer
7.1.7 Eye Cancer
7.1.8 Genitourinary Cancer
7.1.9 Gynecologic Cancer
7.1.10 Head & Neck Cancers
7.1.11 Respiratory/Lung Cancer
7.1.12 Skin Cancer
7.2 Market Segmentation by Cancer Treatment Types
7.2.3 Radiation Therapy
7.2.4 Targeted Therapy
7.2.5 Immunotherapy (Biologic Therapy)
7.2.6 Hormonal Therapy
7.2.8 Stem Cell Transplant
7.2.9 Signal Transduction Inhibitors
7.2.10 Gene Expression Modulators
7.2.11 Apoptosis Inducers
7.2.12 Angiogenesis Inhibitors
7.2.13 Other Therapies
7.3 Market Segmentation by Target Therapy
7.3.1 Targeted Cancer Therapeutics
188.8.131.52 Targeted Cancer Therapy Vs. Chemotherapy
184.108.40.206 Targets for Targeted Cancer Therapy
220.127.116.11 Types of Targeted Cancer Therapy
7.3.2 Hormone Therapy
18.104.22.168 Monoclonal Antibodies
22.214.171.124.1 Naked Monoclonal Antibodies
126.96.36.199.2 Conjugated Monoclonal Antibodies
188.8.131.52.2.1 Radiolabeled Antibodies
184.108.40.206.2.2 Chemolabeled Antibodies
7.4 Market Segmentation by Cancer Vaccines
7.4.1 Vaccines to Help Prevent Cancer
7.4.2 Vaccines to Help Treat Cancer
7.4.3 Non-Specific Immunotherapy
7.5 Market Segmentation by Aromatase Inhibitors
7.5.1 Estrogen Receptors Down Regulators
7.5.2 Hormone Therapy Vs. HRT
7.6 Market Segmentation by Type of Applications
7.6.1 Nasal Spray
7.6.2 Pills or Tablets, Taken by Mouth
7.6.3 Skin Gel
7.6.4 Skin Patches
7.6.5 Vaginal Creams or Vaginal Tablets
7.6.6 Vaginal Ring
7.7 Market Segmentation by Types of Agents
7.7.1 Alkylating Agents
7.7.3 Anti-Microtubule Agents
7.7.4 Topoisomerase Inhibitors
7.7.5 Cytotoxic Antibiotics
7.8 Market Segmentation by Types of Chemotherapy Regimens
7.8.1 Breast Cancer
7.8.3 Germ Cell Tumor
7.8.4 Stomach Cancer
7.8.5 Bladder Cancer
7.8.6 Lung Cancer
7.9 By End-user
7.9.3 Research Centers
8. Market Segmentation by Geography
8.1 North America
8.1.1 United States
9. Company Profiles
9.1 Astrazeneca Plc
9.2 Chugai Pharmaceutical Co., Ltd.
9.3 Genentech Inc.
9.4 Glaxosmithkline Plc
9.5 GPC Biotech Ag
9.6 OSI Pharmaceuticals, Inc.
10. Future outlook of The Market